You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
HEPATITIS B SURFACE ANTIBODY |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2437 Geisinger Epic ID: 45916 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Alternate Collection Container: |
Gold-top (serum separator) microcollection tube
6 mL red-top (plain, non-serum separator) tube
|
|
Specimen required: |
1 mL serum; minimum 0.5 mL, refrigerated. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow serum to clot. Centrifuge to separate serum within 2 hours of collection. | |
Transport temperature: |
Refrigerated. | |
Specimen stability: |
Stable 6 days at 2-8°C, longer if frozen. | |
Rejection criteria: |
Specimen will be rejected if stability limit has been exceeded. Add-ons available only to unopened tube. | |
TEST DETAILS |
||
Interpretation guide: |
Positive: >=11.5 mIU/mL Equivocal: 8.5 - <11.5 mIU/mL Negative: <8.5 mIU/mL |
|
CPT code(s): |
86317 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Qualitative and quantitative detection of antibodies to hepatitis B surface antigen. | |
Methodology: |
Chemiluminescence Immunoassay |
|
Synonyms: |
Anti-HBs, HBsAB, AUSAB Post Hepatitis B vaccine Hepatitis B surface antibody HBSABB
|
|
Clinical significance: |
The presence of the antibody to hepatits B surface antigen (anti-HBs) is used to determine immune status to HBV or disease progression in individuals infected with HBV. An increase in anti-HBs levels, together with a loss of detectable circulating hepatits B surface antigen (HBsAg) denotes convalescence in hepatitis B infections. Furthermore, anti-HBs levels can be measured to determine if vaccination is needed, or following a vaccination regimen, to determine if protective immunity has been achieved. | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu, PhD, DABCC, FADLM Sheng-Ying (Margaret) Lo, PhD, DABCC |
|
| Review Date: | 12/14/2022 | |